nach oben

Erschienen in:

2013 | OriginalPaper | Buchkapitel

9. Systemic Treatment Options for Medical Device-Associated Infection

verfasst von : Oscar Murillo, Jaime Lora-Tamayo, Javier Ariza

Erschienen in: Biomaterials Associated Infection

Verlag: Springer New York

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config

KI-gestützte Suche

Aus

Abstract

Difficulties in eradicating medical device-related infections are primarily related to the presence of bacterial biofilms. The foreign body can often facilitate such infections, which may be usually caused by non-aggressive microorganisms with the ability to form biofilms even at low inoculum size.

The biofilm is responsible for several phenotypic changes in the bacteria including increased minimal bactericidal concentrations (tolerance to antibiotics). Other factors that have also been related to difficulties in the treatment of medical device-related infections are functional abnormalities in the activity of phagocytic cells in contact with the foreign body and the presence of intracellular bacteria.

While the anatomical location of the medical device can determine certain aspects of the treatment of these infections, this therapy must include an appropriate and lengthy antibiotic treatment combined with adequate surgical intervention. Antimicrobial therapy needs to be carefully designed, and the antibiotics to use against device-related infections can be chosen according both to their activity against bacterial biofilms and nongrowing microorganisms, and to their intracellular efficacy.

The specific characteristics of medical device-related infections, as well as the difficulties involved in their treatment, mean that multidisciplinary medical teams are required to ensure the optimal approach to and management of this pathology.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

über 102.000 Bücher
über 537 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Finance + Banking
Management + Führung
Marketing + Vertrieb
Maschinenbau + Werkstoffe
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

über 67.000 Bücher
über 390 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Maschinenbau + Werkstoffe

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Vorheriges Kapitel Tissue Colonization in Biomaterial-Associated Infection

Nächstes Kapitel Preventive Measures Against Transcutaneous Device Infections

Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med. 2004;351(16):1645–54.CrossRef

Del Pozo JL, Patel R. Clinical practice Infection associated with prosthetic joints. N Engl J Med. 2009;361(8):787–94.CrossRef

Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet. 2001;358 (9276):135–8.CrossRef

Chuard C, Lucet JC, Rohner P, Herrmann M, Auckenthaler R, Waldvogel FA, Lew DP. Resistance of Staphylococcus aureus recovered from infected foreign body in vivo to killing by antimicrobials. J Infect Dis. 1991;163(6):1369–73.CrossRef

Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev. 2002;15(2):167–93.CrossRef

Zimmerli W, Lew PD, Waldvogel FA. Pathogenesis of foreign body infection. Evidence for a local granulocyte defect. J Clin Invest. 1984;73(4):1191–200.CrossRef

Proctor RA, Balwit JM, Vesga O. Variant subpopulations of Staphylococcus aureus as cause of persistent and recurrent infections. Infect Agents Dis. 1994;3(6):302–12.

Proctor RA, von Eiff C, Kahl BC, Becker K, McNamara P, Herrmann M, Peters G. Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. Nat Rev Microbiol. 2006;4(4):295–305.CrossRef

Boelens JJ, Dankert J, Murk JL, Weening JJ, van der Poll T, Dingemans KP, Koole L, Laman JD, Zaat SA. Biomaterial-associated persistence of Staphylococcus epidermidis in pericatheter macrophages. J Infect Dis. 2000;181(4):1337–49.CrossRef

10.

Broekhuizen CA, de Boer L, Schipper K, Jones CD, Quadir S, Feldman RG, Dankert J, Vandenbroucke-Grauls CM, Weening JJ, Zaat SA. Peri-implant tissue is an important niche for Staphylococcus epidermidis in experimental biomaterial-associated infection in mice. Infect Immun. 2007;75(3):1129–36.CrossRef

11.

Darouiche RO. Treatment of infections associated with surgical implants. N Engl J Med. 2004;350(14):1422–9.CrossRef

12.

Costerton JW. Biofilm theory can guide the treatment of device-related orthopaedic infections. Clin Orthop Relat Res. 2005;437:7–11.CrossRef

13.

Widmer AF, Frei R, Rajacic Z, Zimmerli W. Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections. J Infect Dis. 1990;162(1):96–102.CrossRef

14.

Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA. 1998;279(19):1537–41.CrossRef

15.

Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284(5418):1318–22.CrossRef

16.

Gilbert P, Collier PJ, Brown MR. Influence of growth rate on susceptibility to antimicrobial agents: biofilms, cell cycle, dormancy, and stringent response. Antimicrob Agents Chemother. 1990;34(10):1865–8.CrossRef

17.

Anwar H, Dasgupta MK, Costerton JW. Testing the susceptibility of bacteria in biofilms to antibacterial agents. Antimicrob Agents Chemother. 1990;34(11):2043–6.CrossRef

18.

Blaser J, Vergeres P, Widmer AF, Zimmerli W. In vivo verification of in vitro model of antibiotic treatment of device-related infection. Antimicrob Agents Chemother. 1995;39(5):1134–9.CrossRef

19.

Zimmerli W, Frei R, Widmer AF, Rajacic Z. Microbiological tests to predict treatment outcome in experimental device-related infections due to Staphylococcus aureus. J Antimicrob Chemother. 1994;33(5):959–67.CrossRef

20.

Farber BF, Kaplan MH, Clogston AG. Staphylococcus epidermidis extracted slime inhibits the antimicrobial action of glycopeptide antibiotics. J Infect Dis. 1990;161(1):37–40.CrossRef

21.

Singh R, Ray P, Das A, Sharma M. Penetration of antibiotics through Staphylococcus aureus and Staphylococcus epidermidis biofilms. J Antimicrob Chemother. 2010;65(9):1955–8.CrossRef

22.

Murillo O, Domenech A, Garcia A, Tubau F, Cabellos C, Gudiol F, Ariza J. Efficacy of high doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother. 2006;50(12):4011–7.CrossRef

23.

Murillo O, Pachon ME, Euba G, Verdaguer R, Carreras M, Cabellos C, Cabo J, Gudiol F, Ariza J. Intracellular antimicrobial activity appearing as a relevant factor in antibiotic efficacy against an experimental foreign-body infection caused by Staphylococcus aureus. J Antimicrob Chemother. 2009;64(5):1062–6.CrossRef

24.

Ellington JK, Harris M, Hudson MC, Vishin S, Webb LX, Sherertz R. Intracellular Staphylococcus aureus and antibiotic resistance: implications for treatment of staphylococcal osteomyelitis. J Orthop Res. 2006;24(1):87–93.CrossRef

25.

Gresham HD, Lowrance JH, Caver TE, Wilson BS, Cheung AL, Lindberg FP. Survival of Staphylococcus aureus inside neutrophils contributes to infection. J Immunol. 2000;164(7):3713–22.

26.

Sendi P, Rohrbach M, Graber P, Frei R, Ochsner PE, Zimmerli W. Staphylococcus aureus small colony variants in prosthetic joint infection. Clin Infect Dis. 2006;43(8):961–7.CrossRef

27.

Maurin M, Raoult D. Intracellular organisms. Int J Antimicrob Agents. 1997;9(1):61–70.CrossRef

28.

Barcia-Macay M, Seral C, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F. Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages. Antimicrob Agents Chemother. 2006;50(3):841–51.CrossRef

29.

Carryn S, Chanteux H, Seral C, Mingeot-Leclercq MP, Van Bambeke F, Tulkens PM. Intracellular pharmacodynamics of antibiotics. Infect Dis Clin North Am. 2003;17(3):615–34.CrossRef

30.

Gov Y, Bitler A, Dell’Acqua G, Torres JV, Balaban N. RNAIII inhibiting peptide (RIP), a global inhibitor of Staphylococcus aureus pathogenesis: structure and function analysis. Peptides. 2001;22(10):1609–20.CrossRef

31.

Balaban N, Giacometti A, Cirioni O, Gov Y, Ghiselli R, Mocchegiani F, Viticchi C, Del Prete MS, Saba V, Scalise G, Dell’Acqua G. Use of the quorum-sensing inhibitor RNAIII-inhibiting peptide to prevent biofilm formation in vivo by drug-resistant Staphylococcus epidermidis. J Infect Dis. 2003;187(4):625–30.CrossRef

32.

Balaban N, Goldkorn T, Gov Y, Hirshberg M, Koyfman N, Matthews HR, Nhan RT, Singh B, Uziel O. Regulation of Staphylococcus aureus pathogenesis via target of RNAIII-activating protein (TRAP). J Biol Chem. 2001;276(4):2658–67.

33.

Balaban N, Cirioni O, Giacometti A, Ghiselli R, Braunstein JB, Silvestri C, Mocchegiani F, Saba V, Scalise G. Treatment of Staphylococcus aureus biofilm infection by the quorum-sensing inhibitor RIP. Antimicrob Agents Chemother. 2007;51(6):2226–9.CrossRef

34.

Garrigos C, Murillo O, Euba G, et al. Study of the efficacy of RNA III inhibiting peptide (RIP) alone and in combination with vancomycin in an experimental foreign-body infection by methicillin-resistan Staphylococcus aureus. 50th International Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010); 2010 Sep 12–15; Boston: B-710

35.

Yasuda H, Ajiki Y, Koga T, Yokota T. Interaction between clarithromycin and biofilms formed by Staphylococcus epidermidis. Antimicrob Agents Chemother. 1994;38(1):138–41.CrossRef

36.

Parra-Ruiz J, Vidaillac C, Rose WE, Rybak MJ. Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm. Antimicrob Agents Chemother. 2010;54(10):4329–34.CrossRef

37.

Tsukayama DT, Estrada R, Gustilo RB. Infection after total hip arthroplasty. A study of the treatment of one hundred and six infections. J Bone Joint Surg Am. 1996;78(4):512–23.

38.

Widmer AF, Gaechter A, Ochsner PE, Zimmerli W. Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations. Clin Infect Dis. 1992;14(6):1251–3.CrossRef

39.

Drancourt M, Stein A, Argenson JN, Zannier A, Curvale G, Raoult D. Oral rifampin plus ofloxacin for treatment of Staphylococcus-infected orthopedic implants. Antimicrob Agents Chemother. 1993;37(6):1214–8.CrossRef

40.

Bahl D, Miller DA, Leviton I, Gialanella P, Wolin MJ, Liu W, Perkins R, Miller MH. In vitro activities of ciprofloxacin and rifampin alone and in combination against growing and nongrowing strains of methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1997;41(6):1293–7.

41.

Eng RH, Padberg FT, Smith SM, Tan EN, Cherubin CE. Bactericidal effects of antibiotics on slowly growing and nongrowing bacteria. Antimicrob Agents Chemother. 1991;35(9):1824–8.CrossRef

42.

Murillo O, Pachon ME, Euba G, Verdaguer R, Tubau F, Cabellos C, Cabo J, Gudiol F, Ariza J. Antagonistic effect of rifampin on the efficacy of high-dose levofloxacin in staphylococcal experimental foreign-body infection. Antimicrob Agents Chemother. 2008;52(10):3681–6.CrossRef

43.

Trampuz A, Murphy CK, Rothstein DM, Widmer AF, Landmann R, Zimmerli W. Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection. Antimicrob Agents Chemother. 2007;51(7):2540–5.CrossRef

44.

San Juan R, Garcia-Reyne A, Caba P, Chaves F, Resines C, Llanos F, Lopez-Medrano F, Lizasoain M, Aguado JM. Safety and efficacy of moxifloxacin monotherapy for treatment of orthopedic implant-related staphylococcal infections. Antimicrob Agents Chemother. 2010;54(12):5161–6.CrossRef

45.

Vindel A, Cuevas O, Cercenado E, Marcos C, Bautista V, Castellares C, Trincado P, Boquete T, Perez-Vazquez M, Marin M, Bouza E. Methicillin-resistant Staphylococcus aureus in Spain: molecular epidemiology and utility of different typing methods. J Clin Microbiol. 2009;47(6):1620–7.CrossRef

46.

Baldoni D, Haschke M, Rajacic Z, Zimmerli W, Trampuz A. Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection. Antimicrob Agents Chemother. 2009;53(3):1142–8.CrossRef

47.

Murillo O, Garrigos C, Pachon ME, Euba G, Verdaguer R, Cabellos C, Cabo J, Gudiol F, Ariza J. Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2009;53(10):4252–7.CrossRef

48.

Bassetti M, Di Biagio A, Cenderello G, Del Bono V, Palermo A, Cruciani M, Bassetti D. Linezolid treatment of prosthetic hip Infections due to methicillin-resistant Staphylococcus aureus (MRSA). J Infect. 2001;43(2):148–9.CrossRef

49.

Bassetti M, Vitale F, Melica G, Righi E, Di Biagio A, Molfetta L, Pipino F, Cruciani M, Bassetti D. Linezolid in the treatment of Gram-positive prosthetic joint infections. J Antimicrob Chemother. 2005;55(3):387–90.CrossRef

50.

Jover-Saenz A, Gaite FB, Ribelles AG, Porcel-Perez JM, Garrido-Calvo S. Linezolid treatment of total prosthetic knee infection due to methicillin-resistant Staphylococcus epidermidis. J Infect. 2003;47(1):87–8.CrossRef

51.

Entenza JM, Moreillon P. Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies. Int J Antimicrob Agents. 2009;34(1):8.e1–9.CrossRef

52.

Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse EJ. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother. 2006;58(6):1221–9.CrossRef

53.

Vaudaux P, Fleury B, Gjinovci A, Huggler E, Tangomo-Bento M, Lew DP. Comparison of tigecycline and vancomycin for treatment of experimental foreign-body infection due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2009;53(7):3150–2.CrossRef

54.

Mascio CT, Alder JD, Silverman JA. Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells. Antimicrob Agents Chemother. 2007;51(12):4255–60.CrossRef

55.

John AK, Baldoni D, Haschke M, Rentsch K, Schaerli P, Zimmerli W, Trampuz A. Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin. Antimicrob Agents Chemother. 2009;53(7) :2719–24.CrossRef

56.

Garrigos C, Murillo O, Euba G, Verdaguer R, Tubau F, Cabellos C, Cabo J, Ariza J. Efficacy of usual and high doses of daptomycin in combination with rifampin versus alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2010;54(12):5251–6.CrossRef

57.

Ariza J, Euba G, Murillo O. Orthopedic device-related infections. Enferm Infecc Microbiol Clin. 2008;26(6):380–90.CrossRef

58.

Roberts JA, Paratz J, Paratz E, Krueger WA, Lipman J. Continuous infusion of beta-lactam antibiotics in severe infections: a review of its role. Int J Antimicrob Agents. 2007;30(1):11–8.CrossRef

59.

Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005;40(9):1333–41.CrossRef

60.

Falagas ME, Kastoris AC, Karageorgopoulos DE, Rafailidis PI. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting Gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. Int J Antimicrob Agents. 2009;34(2):111–20.CrossRef

61.

Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson DL. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis. 2006;6(9):589–601.CrossRef

62.

Meehan AM, Osmon DR, Duffy MC, Hanssen AD, Keating MR. Outcome of penicillin-susceptible streptococcal prosthetic joint infection treated with debridement and retention of the prosthesis. Clin Infect Dis. 2003;36(7):845–9.CrossRef

63.

Euba G, Lora-Tamayo J, Murillo O, Pedrero S, Cabo J, Verdaguer R, Ariza J. Pilot study of ampicillin-ceftriaxone combination for treatment of orthopedic infections due to Enterococcus faecalis. Antimicrob Agents Chemother. 2009;53(10):4305–10.CrossRef

64.

Ivert TS, Dismukes WE, Cobbs CG, Blackstone EH, Kirklin JW, Bergdahl LA. Prosthetic valve endocarditis. Circulation. 1984;69(2):223–32.CrossRef

65.

Calderwood SB, Swinski LA, Waternaux CM, Karchmer AW, Buckley MJ. Risk factors for the development of prosthetic valve endocarditis. Circulation. 1985;72(1):31–7.CrossRef

66.

Karchmer AW, Longworth DL. Infections of intracardiac devices. Infect Dis Clin North Am. 2002;16(2):477–505. Xii.CrossRef

67.

Murdoch DR, Corey GR, Hoen B, Miro JM, Fowler Jr VG, Bayer AS, Karchmer AW, Olaison L, Pappas PA, Moreillon P, Chambers ST, Chu VH, Falco V, Holland DJ, Jones P, Klein JL, Raymond NJ, Read KM, Tripodi MF, Utili R, Wang A, Woods CW, Cabell CH. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med. 2009;169(5):463–73.CrossRef

68.

Gandelman G, Frishman WH, Wiese C, Green-Gastwirth V, Hong S, Aronow WS, Horowitz HW. Intravascular device infections: epidemiology, diagnosis, and management. Cardiol Rev. 2007;15(1):13–23.CrossRef

69.

Baddour LM, Wilson WR, Bayer AS, Fowler Jr VG, Bolger AF, Levison ME, Ferrieri P, Gerber MA, Tani LY, Gewitz MH, Tong DC, Steckelberg JM, Baltimore RS, Shulman ST, Burns JC, Falace DA, Newburger JW, Pallasch TJ, Takahashi M, Taubert KA. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation. 2005;111(23):e394–434.CrossRef

70.

Horstkotte D, Follath F, Gutschik E, Lengyel M, Oto A, Pavie A, Soler-Soler J, Thiene G, von Graevenitz A, Priori SG, Garcia MA, Blanc JJ, Budaj A, Cowie M, Dean V, Deckers J, Fernandez Burgos E, Lekakis J, Lindahl B, Mazzotta G, Morais J, Smiseth OA, Vahanian A, Delahaye F, Parkhomenko A, Filipatos G, Aldershvile J, Vardas P. Guidelines on prevention, diagnosis and treatment of infective endocarditis executive summary; the task force on infective endocarditis of the European society of cardiology. Eur Heart J. 2004;25(3):267–76.CrossRef

71.

Archer GL, Johnston JL, Vazquez GJ, Haywood 3rd HB. Efficacy of antibiotic combinations including rifampin against methicillin-resistant Staphylococcus epidermidis: in vitro and in vivo studies. Rev Infect Dis. 1983;5 Suppl 3:S538–42.CrossRef

72.

Kobasa WD, Kaye KL, Shapiro T, Kaye D. Therapy for experimental endocarditis due to Staphylococcus epidermidis. Rev Infect Dis. 1983;5 Suppl 3:S533–7.CrossRef

73.

Fowler Jr VG, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, Levine DP, Chambers HF, Tally FP, Vigliani GA, Cabell CH, Link AS, DeMeyer I, Filler SG, Zervos M, Cook P, Parsonnet J, Bernstein JM, Price CS, Forrest GN, Fatkenheuer G, Gareca M, Rehm SJ, Brodt HR, Tice A, Cosgrove SE. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355(7):653–65.CrossRef

74.

Marco F, de la Maria CG, Armero Y, Amat E, Soy D, Moreno A, del Rio A, Almela M, Mestres CA, Gatell JM, Jimenez de Anta MT, Miro JM. Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2008;52(7):2538–43.CrossRef

75.

Sakoulas G, Eliopoulos GM, Alder J, Eliopoulos CT. Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2003;47(5):1714–8.CrossRef

76.

Falagas ME, Giannopoulou KP, Ntziora F, Vardakas KZ. Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence. J Antimicrob Chemother. 2007;60(1):7–19.CrossRef

77.

Falagas ME, Manta KG, Ntziora F, Vardakas KZ. Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J Antimicrob Chemother. 2006;58(2):273–80.CrossRef

78.

Miro JM, Del Rio A, Moreno A, et al. Efficacy and safety of fosfomycin plus imipenem for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) native valve endocarditis (NVE): preliminary results of a clinical trial. 48th International Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2008); 2008 Oct 25–28; Washington, DC: L-1523

79.

Sieradzki K, Tomasz A. Suppression of beta-lactam antibiotic resistance in a methicillin-resistant Staphylococcus aureus through synergic action of early cell wall inhibitors and some other antibiotics. J Antimicrob Chemother. 1997;39(Suppl A):47–51.CrossRef

80.

Baddour LM, Bettmann MA, Bolger AF, Epstein AE, Ferrieri P, Gerber MA, Gewitz MH, Jacobs AK, Levison ME, Newburger JW, Pallasch TJ, Wilson WR, Baltimore RS, Falace DA, Shulman ST, Tani LY, Taubert KA. Nonvalvular cardiovascular device-related infections. Circulation. 2003;108(16):2015–31.CrossRef

81.

Bracke FA, Meijer A, van Gelder LM. Pacemaker lead complications: when is extraction appropriate and what can we learn from published data? Heart. 2001;85(3):254–9.CrossRef

82.

Reilly L. Aortic graft infection: evolution in management. Cardiovasc Surg. 2002;10(4):372–7.CrossRef

83.

Kudva A, Hye RJ. Management of infectious and cutaneous complications in vascular access. Semin Vasc Surg. 1997;10(3):184–90.

84.

Yeager RA, Taylor Jr LM, Moneta GL, Edwards JM, Nicoloff AD, McConnell DB, Porter JM. Improved results with conventional management of infrarenal aortic infection. J Vasc Surg. 1999;30(1):76–83.CrossRef

85.

Martinez E, Rello J, Coll P. Clinical diagnosis of ventriculostomy-related infections. Lancet. 1994;344(8928):1015–6.CrossRef

86.

Yogev R, Bisno A. Infections of central nervous system shunts. In: Waldvogel F, Bisno AL, editors. Infections associated with indwelling medical devices. 3rd ed. Washington, DC: ASM Press, 2000; 231–46.

87.

Schreffler RT, Schreffler AJ, Wittler RR. Treatment of cerebrospinal fluid shunt infections: a decision analysis. Pediatr Infect Dis J. 2002;21(7):632–6.CrossRef

88.

Pittet B, Montandon D, Pittet D. Infection in breast implants. Lancet Infect Dis. 2005;5(2): 94–106.

89.

Gabriel SE, Woods JE, O’Fallon WM, Beard CM, Kurland LT, Melton 3rd LJ. Complications leading to surgery after breast implantation. N Engl J Med. 1997;336(10):677–82.CrossRef

90.

Mulcahy JJ. Surgical management of penile prosthesis complications. Int J Impot Res. 2000;12 Suppl 4:S108–11.CrossRef

91.

Wilson SK, Delk 2nd JR. Inflatable penile implant infection: predisposing factors and treatment suggestions. J Urol. 1995;153(3 Pt 1):659–61.

Titel: Systemic Treatment Options for Medical Device-Associated Infection
verfasst von: Oscar Murillo
Jaime Lora-Tamayo
Javier Ariza
Verlag: Springer New York
Buch: Biomaterials Associated Infection
Print ISBN: 978-1-4614-1030-0

Electronic ISBN: 978-1-4614-1031-7

Copyright-Jahr: 2013
DOI: https://doi.org/10.1007/978-1-4614-1031-7_9

Premium Partner

Marktübersichten

Die im Laufe eines Jahres in der „adhäsion“ veröffentlichten Marktübersichten helfen Anwendern verschiedenster Branchen, sich einen gezielten Überblick über Lieferantenangebote zu verschaffen.

Zur Marktübersicht